Pradaxa Linked to Fatal Bleeding Events

by Cary Graham | March 28th, 2017

Non-valvular atrial fibrillation or AFib is an irregular and often rapid heart rate that can cause heart palpitations, fatigue, and shortness of breath. Traditionally, this condition was treated with Coumadin (warfarin), an anticoagulant drug approved more than 60 years ago. The downside of Coumadin is it requires monthly blood tests and adherence to strict dietary requirements. A newer drug known as Pradaxa does not have these limitations, which is why it has become a popular alternative among physicians for reducing the risk of stroke in patients with AFib. However, in recent years, its popularity has waned due to a series of fatal bleeding events linked to the medication.

In 2008, the manufacturer of Pradaxa reported 260 fatal bleeding events related to the drug leading to a full FDA investigation into the risk. Those especially susceptible to increased risk of abdominal bleeding while taking Pradaxa include those who:

  • are 75 years old or older.
  • have existing kidney problems.
  • have stomach bleeding or an ulcer.
  • are taking other drugs that can increase the risk of bleeding, including aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and other blood thinners.

If you or someone you love has been hospitalized for severe bleeding after taking Pradaxa, the drug injury lawyers at Ferrer, Poirot & Wansbrough want to help. You may be eligible for compensation for medical expenses, lost wages, and more. Give us a call today for a free evaluation of your claim.